Ligand to Present at the Oppenheimer Healthcare Conference on December 14
Save-the-Date: Ligand Hosting Promacta Panel Discussion on November 7
Ligand to Report Third Quarter Results on November 8
Ligand Enters into Platform Captisol® License Agreement with SAGE Therapeutics
Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn®
Ligand to Present at the BioCentury NewsMakers Conference on October 21
Ligand Pharmaceuticals Announces Second Quarter Results
Ligand to Report Second Quarter Results on August 8th
Ligand Partner GlaxoSmithKline Receives Positive Data from Promacta(R) PIII ENABLE1 Study in Hepatitis C-Related Thrombocytopenia
Ligand to Advance Clinical Development of Captisol-enabled(R), Propylene Glycol-Free Melphalan for Multiple Myeloma
Reminder: Ligand to Webcast Analyst and Investor Day on June 23 in New York City
Ligand Enters into Captisol(R) Commercial Supply Agreement with Merck
Ligand Presents Phase IIa Data on Captisol(R)-Enabled, Propylene Glycol-Free Melphalan at ASCO 2011
Ligand Presents Multi-Dose Phase I Data on Lead SARM Molecule LGD-4033 at the Endocrine Society Annual Meeting
